Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Lab 3 > Mucosal drug delivery > Flashcards

Mucosal drug delivery Flashcards

1
Q

What are mucosal membranes?

A

epithelial membranes with a layer of mucus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What surfaces do mucosal membranes line? Give some examples.

A

hollow organs/body cavities exposed to external environment
eg digestive, respiratory, reproductive system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the functions of mucosal membranes?

A
  • provide hydration, lubrication
  • protective barrier
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the composition of mucus?

A

viscoelastic hydrogel composed of:

  • cross-linked mucin fibres
  • cell/cell debris
  • microbiota and secretions
  • DNA, proteins, Ig, lysozyme, lactoferrin
  • lipids, polysaccharides
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

whys it hard to deliver NPs through or across mucosal memb?

A

its a protective barrier function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Generic structure of mucin monomer

A

oligonucleotides stuck to repeat structure and cysteine residues between

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is an example of microbiota and secretions found within mucus?

A

microbes in the vagina secrete lactic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What can impact the mucus composition and properties? 2

A

anatomical site and disease state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the two properties of mucus that can vary?

A

pH
layer thickness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

pH of resp tract?

A

neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the pH of mucus in the ocular, distal colonic and endo-cervical membranes?

A

slightly basic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the pH of mucus in the vagina?

A

slightly acidic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the pH of mucus across the gastric lumen to epithelium?

A

transitions from acidic in lumen to neutral in epithelium
gradient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the thickness of mucus in the nasal cavity?

A

thin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the thickness of mucus in the stomach and colon?

A

thick, but can vary depending on digestive activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What example shows that mucus thickness can vary in disease states?

A

cystic fibrosis - thick, sticky mucus in the lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Why is mucus a difficult barrier to cross for drug delivery?

A
  • dynamic properties: high turnover rates
  • composition: strong adhesive forces
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What thickness of mucus has the fastest turnover rate?

A

thin:

  • nasal cavity and respiratory tract replenished every 10-20min
  • eyes turnover rate of 13-20% every minute
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the implication of mucus turnover on the nanomedicine?

A

nanomedicine residence time is shortened as it can be turned over with the mucus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the 2 types of strong adhesive forces that mucus can form with nanomedicines and why?

A
  • electrostatic: due to negative charge on mucus
  • hydrophobic: presence of hydrophobic domains (originally to minimise transport of bacteria)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Why do we delivery nanomedicine to mucosal surfaces?

A

same reasons we use nanomedicines in general:

  • sustained/controlled drug release
  • protect drug from degradation (mucus also has enzymes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the goal of mucoadhesive nanomedicines?

A

want to adhere to mucus
to prolong its residence time in memb, maybe to facilitate enhanced absorption of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the goal of mucopenetrating nanomedicines?

A

penetrate mucus to reach epithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are two approaches to achieving mucoadhesion with nanomedicines?

A

non-specific and specific binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the non-specific binding used to achieve mucoadhesion?

A

electrostatic forces or H bonds
this is targeting the natural property of the mucus rather than a specific mucus component

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How can mucoadhesion be achieved through electrostatic attractions?

A

coat NPs with either:

  • positively charged polymer so it can interact w negative charge of mucus
  • negatively charged/neutral polymer to get H bonding in components of mucus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is an example of a cationic polymer used to achieve mucoadhesion through electrostatic forces?

A

chitosan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is an example of a neutral polymer used to achieve mucoadhesion through H bonds?

A

cellulose + derivatives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are examples of anionic polymers used to achieve mucoadhesion through H bonds?

A
  • poly(acrylic acid) + derivatives
  • sodium alginate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Sodium alginate combinations to achieve mucoadhesion through H bonds

A

gellan gum
xanthan gum
carrageenan (sulfate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Poly(acrylic acid) + derivatives to achieve mucoadhesion through H bonds

A

polycarbopol
carbomer
carmellose
carbopols

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the specific binding used to achieve mucoadhesion?

A
  • covalent bonds
  • lectins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What covalent bonds are used to achieve mucoadhesion?

A
  • disulphide bridges
  • interact thiolated polymers (R-SH) and cysteine residues

and Cysteine found in mucin fibres

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

How do lectins work to achieve mucoadhesion? (what are they?)

A

they’re carbohydrate-binding glycoproteins
attach to NM surface to allow active targeting of NPs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What is the disadvantage of lectins?

A
  • can permeate through mucus and enter cell
  • immunogenicity?
  • toxicity?
  • therefore need to consider lectin choice carefully
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Particles of what size cannot penetrate the mucus and are cleared away quickly? Why?

A

> 1000nm - too big to squeeze through pores of mucus meshwork created by mucin fibres

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Particles of what size are the best for mucopenetration? Why?

A

mid range - 200-500nm

any smaller means they become stuck in ‘dead-end’ structures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What are the ideal characteristics of mucopenetrating particles?

A
  • small enough to fit through mucus pores
  • inert/ non-adhesive to avoid binding to mucus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

whats the ultimate fate of bigger particles not able to penetrate mucus memb?

A

mucus memb turned over at some point and big particles taken out

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Mucus-penetrating particles must overcome what 2 things?

A

adhesive and steric
(size and trafficking through pores) barriers…

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What are strategies we can use to create mucopenetrating particles?

A
  • mask surface charge and hydrophobicity w polymers
  • add mucolytic agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What polymers can be used to mask surface charge and hydrophobicity for mucopenetration?

A
  • PEG
  • Pluronic F-127
  • Poly(vinyl alcohol)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What are the issues with PEG to help mucopenetration?

A
  • people could have anti-PEG antibodies due to prior exposure in personal care products
  • masking surface properties hinders cell uptake
  • can also be mucoadhesive if high MW
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

high MW PEG has low Dm/Dw value (particle coating) what does this mean?

A

not good surface penetration
promotes mucoadhesion instead.

Long chain PEGs may get tangled up and create a steric barrier… making particles stick in mucus/formation of interpenetrating polymer networks: long chain PEGs intercalate with mucin fibres in mucus -> stick

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

what is Dm/Dw? and what values are desirable?

A

relative diffusion of these particles in mucus relative to diffusion in water

System that penetrates well through mucus has high Dm/Dw. Want as close to 1 = better penetration.

46
Q

if you have 2 2kDas PEGs (essentially same PEG coating but diff weights), whats the reason for difference in surface penetration/ Dm/Dw?

A

Not having good coverage of surface, not masking fully and well = not getting best mucopenetration possible.

47
Q

what sort of NPs: hydrophobic or hydrophilic have low Dm/Dw ?

A

hydrophobic NPs with no coating = very low Dm/Dw. Not good penetration. Getting hydrophobic interactions between surface and hydrophobic pockets

Number increase with coating with PEG and high coverage

48
Q

What must be correct about PEG to achieve mucopenetration?

A
  • needs low MW
  • needs high density (higher coverage w no exposed parts)
49
Q

pluronic F-127 is an alternative to PEG.
its a triblock copolymer working similar to PEG, but requires a poly(propylene oxide) PPO segment that’s >3kDa for MoA

name 2 benefits of using it over PEG

A

can pre-make nanomedicine and pluronic F-127 will physically adsorb to NP surface

50
Q

What are the issues with pluronic F-127?

A
  • stability of coverage
  • masking surface properties hinders cell uptake
51
Q

What is an alternative to PEG and pluronic F-127?

A

poly(vinyl alcohol)

has hydroxyl group (hydrophilic)
acetate group (hydrophobic)

52
Q

mucolytic agents aid mucopenetration by disrupting the mucus layer. how can they do this?

A
  • enzymatic degradation of proteins
  • degradation of entangled DNA
  • reduction of disulfide bonds
53
Q

What is an example of a mucolytic agent that works by degrading entangled DNA in the mucus?

A

recombinant human DNAse

54
Q

What is an example of a mucolytic agent that works by reducing disulfide bonds?

A

N-acetyl-L-cysteine (NAC)

Formed between thiol groups. Lots of cysteine residues in mucus. Form disulphoide bridges with thiol groups on NM, but also with each other! Lots of cross links in mucus. NAC opens up mucus structure by reducing these = easier for NM to get through

55
Q

size modulation: what size particles
- increase mucoadhesion
- decrease mucoadhesion

A
  • 100nm
  • 200-500nm

???

56
Q

what 3 surface chemistry changes will increase mucoadhesion.

what 1 will decrease it?

A

+ve charge
mucoadhesive polymers
hydrophobic surface

dense PEGylation :(

57
Q

Part 2: Mucosal delivery applications……

pulmonary delivery: why target the lung for local admin?

A

treat lung diseases
potential targets: epithelial cells and alveolar macrophages

57
Q

pulmonary delivery: why target the lung for systemic admin?

A
  • Large SA for absorption
  • Low thickness of epithelial barrier (mucosal membrane quite thin too)
  • Low enzyme activity
  • Extensive vascularisation: blood supply
58
Q

where do the smallest size (0-1um) NPs deposit in lungs?

A

alveolar region
some in airways

59
Q

where do the mid size (1-5um) NPs deposit in lungs?

A

highest % in alveolar region

60
Q

where do the largest size (5um+) NPs deposit in pulmonary system?

A

mouth and throat, airways

61
Q

smaller NPs given IV, dont even reach lungs, but more accumulate where?

A

liver and spleen

62
Q

problem with admin larger particles IV for pulmonary delivery?

A

block smaller capillaries and cause embolism :(

thus non inhalatory admin of NMs not best way to get to lung

63
Q

assessing how hydrophobic surface of NP and found high HIC index associated with?

A

adverse effects/ tox in lung

64
Q

whats a good HIC index score for NPs to have (hydrophobicity) to exhibit no adverse effects?

A

low
< 0.7

65
Q

What is the main risk of using nanoparticles for pulmonary drug delivery?

A

High nanoparticle hydrophobicity increases toxic side effects.

66
Q

What characteristics can be manipulated for PASSIVE targeting pulmonary drug delivery?

(exploiting natural physiology of lung)

A

Size
Charge
Surface proteins

67
Q

Active targeting in pulmonary delivery involves sticking targeting moiety to NP surface: antibody/ protein that will interact with particular receptor.

What can be targeted in ACTIVE targeting in pulmonary drug delivery?

A

Alveolar macrophages
Bronchial epithelial targets

68
Q

How can alveolar macrophages be actively targeted?

A

(first line of immune defence)

By targeting mannose receptors

69
Q

give examples of diseases that use Alveolar macrophages as a target

A

TB
CF
AIDS

70
Q

targeting macrophages may not be best for specific delivery why?

A

Non-specific target (Kupffer cells in liver, peritoneal macrophages), as have macrophages in other sites of body, may be affected too.
Consider ROA

71
Q

when passively targeting alveolar macrophages, as particles increase in size, how is uptake affected?

A

increases too

Makes sense: if want to target alveolar macrophages, make bigger particles. Job of alveolar macrophages: recognise and clear up foreign particles). If make higher nm particles, approximatimating size of bacteria, exploiting natural function of alveolar macrophages through making specific size particles and encouraging uptake/ passive targeting

72
Q

Why are mannose receptors a good target to target alveolar macrophages?

A

They are exclusive to alveolar macrophages within the lung.

BUT still have some elsewhere: peritoneal, kupffer cells (liver)

73
Q

If you put drug in gelatin parts, what affect does this have on residence time in plasma regardless of mannose?

(experiment)

A

increases.
NM via non-inhalational route dont go to lungs, most to liver

74
Q

What is lactoferrin? and its use

A

iron binding glycopritein
for Active targeting of epithelial cells (bronchial epithelial…)

75
Q

lactoferrin has Ubiquitous distribution.
what does this mean?

A

its everywhere in body
- secreted by epithelial cells into most exocrine fluids e.g. tears, sweat, milk
So have to be careful if using as active targeting

76
Q

lactoferrin is used for active targeting of bronchial epithelial cells why?

A

as receptors are overexpressed on apicalside of those cells

77
Q

lactoferrin has a role in many processes including:

A
  • Antimicrobial, immunomodulatory, antiviral, and anti-metastasis activity
  • Bacterial defense within the respiratory tract
78
Q

What are potential limitations to using lactoferrin to target epithelial cells?

A

May not be applicable to every disease.
Degradation by proteases, as it is itself a protein

79
Q

What are the benefits of mucosal administration?

A

Route of entry for pathogens.
Ease of administration
Local and systemic immunity.

80
Q

why would you want to initiate immune response at mucosal memb/ site?

A

Route of entry for pathogens. An interphase between inside and outside world.

81
Q

give some examples of mucosal vaccines used on the market?

A

polio
cholera
flu

82
Q

mucosal immune system composed of what 2 sites?

A

inductive
effector

83
Q

What are inductive sites in the mucosal immune system?

A

where immune responses are initiated

84
Q

What are effector sites in the mucosal immune system?

A

where effector cells get involved and mediate the immune response

85
Q

What are the 3 types of Mucosae-associated lymphoid tissue (MALT)?

A

Gut
Broncheal
Nasal

GALT, BALT, NALT

86
Q

how many types of Mucosal immune system (MALT) are there and what are the differences?

A

2
type I: IgA
typeII: IgG, no M cells

87
Q

What effector molecule mediates response for Type 1 MALT?

A

IgA

88
Q

What effector molecule mediates response for Type 2 MALT?

A

IgG

89
Q

name of the cells involved in MALT..

characteristic: interspersed in cell layer of a mucosal membrane.
Really different in function to epithelial cell. Key part of immune system.
Tend to mediate transport of antigens/ pathogens from lumen across mucosal membrane to other immune structures.

A

Microfold (M) cells

90
Q

involved in MALT Type II are Specific types of antigen presenting cells e.g. ?

A

dendritic Langerhans cells

91
Q

4 characteristics of good ideal vaccine dleivery system?

A

Protective (of antigen inside)
Targeted delivery
Effective
Safe and (not immunogenic) in itself

92
Q

what should ideal vaccines protect?

A

antigen inside and prevent degradation of vaccine

93
Q

why should ideal vaccines provide targeted delivery?

A

Increased accumulation at inductive sites (MALT…)- where mucosal immune response kicks off
Avoid entrapment in mucus layer. How to avoid mucoadhesion… from before

94
Q

how would vaccines be termed effective? if they are able to do what?

A

Able to stimulate immune response to pathogen

95
Q

How can adjuvants improve mucosal vaccines efficacy?

A

Can help reduce the dose and enhance immune response. (by alerting immune response to danger)

96
Q

common parenteral adjuvants used?

A

o Aluminium salts
o Emulsions

97
Q

What is immune stimulating complex (ISCOM)?

A

particle based vaccine adjuvant
3D, open cage-like structures (30-70 nm)

98
Q

What is immune stimulating complex (ISCOM)?

A

particle based vaccine adjuvant
3D, open cage-like structures (30-70 nm)

99
Q

what is ISCOM a mixture of?

A

o Phospholipids
o Cholesterol
o Quil A (soap bark tree extract) some detergent activity,– punch holes in membranes - immunoadjuvant

Antigen incorporation into lipid network

100
Q

can improve mucosal vaccines by targeting M cells in type I.
2 ways to do this

A

passively or actively

101
Q

Why would you target M cells in mucosal vaccines?

A

M cells are where the immune response starts

102
Q

what parameters are of importance for passive targeting of mucosal vaccines to M cells

A

size (internalisation, drug loading)
surface chem
-charge
-hydrophobicity
-adhesion to M cells

All things BAD and cause premature clearing of NPs loaded w drug from blood by MPS, are GOOD for targeting vaccines to M cells

103
Q

what does active targeting of mucosal vacicnes – targeting M cells (in Type I) involve?

A

attaching moeity to surface

104
Q

2 examples of active targeting of mucosal vacicnes – targeting M cells (in Type I) involve?

A

Cholera toxin B
-Adjuvant properties (2 in 1, with active targ)
-Risk of CNS inflammation – in brain. Very careful especially if using for nasal, as clear pathway to brain

UEA (Ulex europaeus agglutinin I)
-Selective binding to M cells in Peyer’s patches
-Clinical relevance?

105
Q

Why does the innate immune system need to be triggered in mucosal vaccine delivery?

A

active targeting is not enough and good efficacy is difficult to achieve.

(inborn defense system) fairly general and non specific immunity

106
Q

Adaptive immune system forms exposure and vaccinations over life.

role/ use of:
- adjuvants
- hydrophobic surface
- DAMPs

A
  • alert immune system to danger
  • to trigger IS
  • release effector mols and start immune response
107
Q

What else can be targeted to improve mucosal vaccines?
why?

A

dendritic cells
- Typical cell type in type II mucosa
- Antigen presenting cells.

Lectin ligand (Active targeting), antibodies, mannose receptors (on macrophages + dendritic)

Impact on:
- Intracellular routing
- Antigen presentation
maybe improving uptake of DDS by antigen presenting cell -> help immune response kick off and start

108
Q

Mucosal vaccines and formulation: 2 ways to improve?

A
  • Incorporate vaccine into NP to offer protection
  • Employ targeting strategy
109
Q

Describe the ways in which nanoparticles can act with antigens is vaccine delivery? 4

A

Conjugation
Encapsulation
Adsorption
Mix

110
Q

What are the challenges for using mucosal vaccines?

A

Dosing
Frequency
Tolerance (not always bad- allegens)
infection/inflamm

May be induced by prolonged release of low doses (loss of adjuvant effect)…
… but also by burst release of high antigen doses

Lab 3 (21 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions